Laguna Pharmaceuticals Obtains $30,000,000 Series B Funding Round

  • Feed Type
  • Date
    2/17/2015
  • Company Name
    Laguna Pharmaceuticals
  • Mailing Address
    Undisclosed La Jolla, CA 92130 USA
  • Company Description
    Laguna Pharmaceuticals, formerly known as ChanRx, is a biopharmaceutical company advancing vanoxerine for treatment of atrial fibrillation and atrial flutter.
  • Website
    http://www.lagunarx.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $30,000,000
  • Transaction Round
    Series B
  • Proceeds Purposes
    Laguna Pharmaceuticals plans to use the proceeds to progress Phase 3 clinical development of its lead compound, vanoxerine, a therapeutic drug candidate for the treatment of atrial fibrillation (AF) and atrial flutter (AFL).
  • M&A Terms
  • Venture Investor
  • Venture Investor
  • Venture Investor
  • Venture Investor

Trending on Xconomy